GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance

GeneDx Holdings Corp.

Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).
Exome/genome volume 30,785 (+32% YoY); adjusted gross margin 70% (GAAP 68%).
Adjusted net income $0.4M (up $8.6M from Q1); GAAP net loss $17.7M.
Reiterates FY2026 revenue guidance $475-490M with exome/genome volume growth at least 30%.
Amended Blackstone loan: additional $50M term loan (total $150M); Blackstone bought $5M stock at $61/share; pro forma cash ~$188M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.